PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1536.00 - 1565.00
1090.00 - 1784.00
46.2K / 155.6K (Avg.)
23.48 | 66.41
Steady, sustainable growth is a hallmark of high-quality businesses. Value investors watch these metrics to confirm that the company's fundamental performance aligns with—or outpaces—its current market valuation.
-77.57%
Both firms have declining sales. Martin Whitman would suspect an industry slump or new disruptive entrants.
-73.55%
Negative gross profit growth while 5715.T is at 12.06%. Joel Greenblatt would examine cost competitiveness or demand decline.
-116.51%
Negative EBIT growth while 5715.T is at 312.74%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.
-118.68%
Negative operating income growth while 5715.T is at 60.76%. Joel Greenblatt would press for urgent turnaround measures.
-121.43%
Negative net income growth while 5715.T stands at 287.40%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.
-121.44%
Negative EPS growth while 5715.T is at 287.36%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.
-121.44%
Negative diluted EPS growth while 5715.T is at 287.36%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-77.61%
Negative 10Y revenue/share CAGR while 5715.T stands at 50.12%. Joel Greenblatt would question if the company is failing to keep pace with industry changes.
50.02%
5Y revenue/share CAGR above 1.5x 5715.T's 22.61%. David Dodd would look for consistent product or market expansions fueling outperformance.
85.71%
3Y revenue/share CAGR above 1.5x 5715.T's 5.31%. David Dodd would confirm if there's an emerging competitive moat driving recent gains.
100.00%
Positive long-term OCF/share growth while 5715.T is negative. John Neff would see a structural advantage in sustained cash generation.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
91.63%
Below 50% of 5715.T's 546.59%. Michael Burry would worry about a sizable gap in long-term profitability gains vs. the competitor.
-139.20%
Negative 5Y net income/share CAGR while 5715.T is 186.69%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.
32.86%
3Y net income/share CAGR 1.25-1.5x 5715.T's 26.74%. Bruce Berkowitz might see new markets, M&A, or better cost discipline driving the difference.
No Data
No Data available this quarter, please select a different quarter.
60.67%
5Y equity/share CAGR is in line with 5715.T's 60.50%. Walter Schloss would see parallel mid-term profitability and retention policies.
36.59%
3Y equity/share CAGR above 1.5x 5715.T's 19.54%. David Dodd verifies the company’s short-term capital management far exceeds the competitor’s pace.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-21.76%
Both reduce receivables yoy. Martin Whitman suspects a shift in the entire niche’s credit approach or softer demand.
21.96%
We show growth while 5715.T is shrinking stock. John Neff wonders if the competitor is more disciplined or has weaker demand expectations.
-2.55%
Negative asset growth while 5715.T invests at 2.27%. Joel Greenblatt checks if the competitor might capture more market share unless our returns remain higher.
-2.55%
Both erode book value/share. Martin Whitman suspects a difficult environment or poor capital deployment for both players.
11.29%
Debt growth far above 5715.T's 7.92%. Michael Burry fears the firm is taking on undue leverage vs. the competitor.
-81.04%
Both reduce R&D yoy. Martin Whitman sees an industry shifting to cost reduction or limited breakthroughs in the near term.
-20.42%
We cut SG&A while 5715.T invests at 30.89%. Joel Greenblatt sees a short-term margin benefit but wonders if the competitor invests for future gains.